Boehringer Ingelheim Pharmaceuticals, Inc. has received FDA approval for the oral prescription drug NERANDOMILAST (NDA218764), branded as JASCAYD. This milestone could significantly impact the market, particularly in the targeted indication where Boehringer's product is positioned against Teva Pharmaceutical's recently approved Ozenudil, representing a new competitive entry for the substance.